European Journal of Cancer
Volume 41, Issue 6 , Pages 908-921 , April 2005

Technological advances in radiotherapy for the treatment of localised prostate cancer

Received 4 October 2004 ,Accepted 2 December 2004.

References 

  1. Bagshaw MA, Kaplan HS, Sagerman RH. Linear accelerator supervoltage therapy:VII. Carcinoma of the prostate. Radiology. 1967;85:121–129
  2. Ray GR, Cassady JR, Bagshaw MA. Definitive radiation therapy for carcinoma of the prostate. Radiology. 1973;106:407–418
  3. Bagshaw MA. Definitive megavoltage radiation therapy in carcinoma of the prostate. In:  Fletcher GH editors. Textbook of radiotherapy. 2nd ed.. Philadelphia, PA: Lea & Febiger; 1973;p. 752–767
  4. Bagshaw MA. External radiation therapy of carcinoma of the prostate. Cancer. 1980;45:1912–1921
  5. Liebel SA, Zelefsky MJ, Kutcher GJ, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol. 1994;21:580–597
  6. Horowitz EM, Hanks GE. External beam radiation for prostate cancer. CA Cancer J Clin. 2000;50:349–375
  7. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localised prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;28:1598–1604
  8. Zagars GK, Pollack A, Smith LG. Conventional external beam radiation therapy alone or with androgen ablation for clinical stage III (T3, Nx/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999;44:809–819
  9. Epstein BE, Hanks GE. Radiation therapy techniques and dose selection in the treatment of prostate cancer. Semin Radiat Oncol. 1993;3:179–186
  10. Hancock S, Cox R, Bagshaw M. Prostate specific antigen after radiotherapy for prostate cancer: a re-evaluation of long term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol. 1995;154:1412–1417
  11. Zietman A, Coen J, Dallow K, Shipley W. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995;32:287–292
  12. Laverdière J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiotherapy in localised prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:247–252
  13. Photon Treatment Planning Collaborative Working Group. Three dimensional dose calculations for radiation treatment planning. Int J Radiat Oncol Biol Phys 1991;21:25–36
  14. Liebel SA, Zelefsky MJ, Kutcher GJ, et al. The biological basis and clinical application of three dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol. 1994;21:580–597
  15. Mohan R, Barest G, Brewster LJ, et al. A comprehensive three dimensional conformal radiation therapy and intensity modulated radiation therapy systems. Int J Radiat Oncol Biol Phys. 1988;15:481–495
  16. Hanks GE, Scultheiss TE, Hunt MA, Epstein B. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1995;31(1):25–29
  17. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353(91949):267–272
  18. Jackson A, Zelefsky MJ, Cowan D, et al. Rectal bleeding after conformal radiotherapy of prostate cancer and dose volume histograms. Int J Radiat Oncol Biol Phys. 1998;42:217
  19. Vicini FA, Martinez A, Hanks G, et al. An interinstitutional and interspeciality comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002;95(10):2126–2135
  20. Hanks GE, Liebel SA, Krall JM, et al. Patterns of care studies: dose response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1985;11:153–157
  21. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localised prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18(14):2740–2746
  22. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–1105
  23. Smit WGJM, Helle PA, Van Putte WLJ, et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18:23–29
  24. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British J Cancer. 2005;92:488–498
  25. Dearnaley DP, Arid E, Bidmead AM, et al. High dose conformal radiotherapy in localised prostate cancer: the MRC RTO1 trial. Proc ASCO. 2002;21:769
  26. Liebel SA, Fuks Z, Zelefsky MJ, et al. Intensity-modulated radiotherapy. Cancer J. 2002;8:164–176
  27. Ling CC, Burman CM, Chui CS, et al. Conformal radiotherapy treatment of prostate cancer using inversely planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys. 1996;35:721–730
  28. Burman CM, Chui CS, Kutcher GJ, et al. Planning, delivery, and quality assurance of intensity- modulated radiotherapy using dynamic multileaf collimator: a strategy for large scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39:863–873
  29. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53(5):1111–1116
  30. Nutting CM, Corbishley CM, Sanchez-Nieto B, et al. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol. 2002;75(890):151–161
  31. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localisation of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging, and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164:400–404
  32. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med. 1997;337(5):295–300
  33. Zeitman A, Prince E, Nakfoor B, et al. Neodajuvant androgen suppression with radiation in the management of locally advanced prostate cancer: experimental and clinical results. Urology. 1997;49(suppl 3A):74–83
  34. Forman JD, Kumar R, Haas G, et al. Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest. 1995;13(1):8–15
  35. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III Radiation Oncology Group (RTOG) Trial 86-10 adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243–1252
  36. Laverdiere J, Nabid A, DeBedoya LD, et al. The efficacy and sequencing of short course androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2–T3 prostate cancer. J Urol. 2004;171(3):1137–1140
  37. Hanks G, Machtay M, Venkatesan V, et al. Proceedings of the American Society on Thermal Radiation Oncology (ASTRO), RTOG Protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243–1252
  38. Pilepich M, Winter K, Lawton C, et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long term results of Phase III Study 85-31. Proceedings of American Society on Theramal Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2003;57(2):S172–S173(pres as oral pres)
  39. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47(3):609–615
  40. Kirk D. Re: a structured debate – immediate versus deferred androgen suppression in prostate cancer – evidence for deferred treatment. J Urol. 2002;167(2 Pt-1):652;discussion 653
  41. Simon D, Charles MA, Nahoul K, et al. Association between plasma testosterone and cardiovascular risk factors in healthy adult men: the Telecom study. J Clin Endocrinol Metab. 1997;82(2):682–685
  42. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–4267
  43. D’AmicoAV , Manola J, Loffredo M, et al. 6 month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer – a randomised controlled trial. JAMA. 2004;292(7):821–827
  44. Brenner PA, Dale R, Orton C, et al. Radiobiogy of HDR, LDR, and PDR brachytherapy. In:  Joslin CA,  Flynn A,  Hall EJ editor. Principles and practices of brachytherapy. New York: Oxford University Press Inc.; 2001;p. 189–204
  45. Pasteau O. Traitment du cancer de la prostate par le radium. Rev Malad. Nutrition. 1911;363–367
  46. Whitmore W, Hilaris B, Grabstald H. Retropubic implantation of iodine-125 in the treatment of iodine-125 in the treatment of prostate cancer. J Urol. 1972;108:918–920
  47. Sylvester J, Blasko JC, Grimm P, et al. Interstitial implantation techniques in prostate cancer. J Surg Oncol. 1997;66(1):65–75
  48. Ling C. Permanent implants using Au-198, Pd-103, and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys. 1992;37:81–87
  49. Prestidge BR, Prete JJ, Bucholz TA. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 1999;40:461–465
  50. Wallner K, Merrick G, True L, et al. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes form a prospective randomised multicentre trial. Cancer J. 2002;8(1):67–73
  51. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy doses: recommendations of the AAPM Radiation Therapy Committee Task Group No 43. Med Phys. 1995;22:209–233
  52. Alvaro A, Martinez M, Gustafon G, et al. Dose escalation using conformal high dose-rate brachytherapy improves outcome in unfavourable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(2):316–327
  53. Hoskin PJ. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiother Oncol. 2000;57:285–288
  54. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171(3):1109–1110
  55. Eshleman JS, Davis BJ, Pisansky TM, et al. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004;59(2):419–425
  56. King CR. LDR vs HDR brachytherapy for localised prostate cancer: the view from radiobiological models. Brachytherapy. 2002;1(4):219–226
  57. Blasko J, Wallner K, Grimm P, et al. Prostate specific antigen based decrease control following ultrasound guided iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Urol. 1995;154:1096–1099
  58. Wallner K, Roy J, Harrison L. Tumour control and morbidity following transperineal I-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 1996;14:449–453
  59. Dattoli M, Wallner K, Sorace R, et al. 103 Pd brachytherapy and external beam irradiation for clinical localised, high risk prostate carcinoma. Int J Radiat Oncol Biol Phys. 1996;41:263–265
  60. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160(4):1379–1382
  61. Brosman SA, Tokota K. Transrectal ultrasound guided interstitial radiation therapy for localised prostate cancer. Urology. 1991;38:276–372
  62. Hu K, Wallner K. Rectal and urinary morbidity in patients undergoing prostate I-125 implant. Int J Radiat Oncol Biol Phys. 1997;39(Abstr):292
  63. Merrick GS, Butler WM, Tollenaar BG, et al. The dosimetry of prostate brachytherapy induced stricture. Int J Radiat Oncol Biol Phys. 2002;52(2):461–468
  64. Zelefsky MJ, Hollister T, Raben A, et al. Five year biochemical outcome and toxicity with transperineal CT-planned permanent implantation for patients with localised prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47(5):1261–1266
  65. Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55(2):342–353
  66. Arterberry VE, Frazier A, Dalmia P, et al. Quality of life after permanent prostate implant. Semin Surg Oncol. 1997;13:461–464
  67. Raina R, Agarwal A, Goyal KK, et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology. 2003;62(6):1103–1108
  68. Ragde H, Korb LJ, Elgamal AA, et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000;89(1):135–141
  69. Zietman AL. Localised prostate cancer: brachytherapy. Curr Treat Options Oncol. 2002;3(5):429–436
  70. Martinez A, Galalae R, Gonzalez J, et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol. 2003;170(6 Pt1):2296–2301
  71. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 2001;51(1):213–214
  72. Lukka H, Hayter C, Warde P et al., Investigators of OCOG Prostate Fractionation/ NCIC CTG PR5 Study. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57(2)suppl 1 (abstr:S126)
  73. Livesey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57(5):1254–1259
  74. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localised prostate cancer with daily transabdominal ultrasound localisation of the prostate gland. Int J Radiat Oncol Biol Phys. 2000;46:575–580
  75. Langen KM, Pouliot J, Anezinos RTT, et al. Evaluation of ultrasound-based prostate localisation for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):635–644
  76. Artigan X, Monique HP, Smitsmans MD, et al. Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on prostate displacement. Int J Radiat Oncol Biol Phys. 2004;59(2):595–601
  77. Dehnad H, Nederveen AJ, van der Heide UA, et al. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol. 2003;67(3):295–302
  78. Pouliot J, Aubin M, Langen KM, et al. (Non)- migration of radiopaque markers used for on-line localisation of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003;56(3):862–866
  79. Kitamura K, Shirato H, Seppenwoolde Y, et al. Three dimensional intrafractional movement of prostate measured during real-time tumour-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys. 2002;53(5):1117–1123
  80. Khoo VS, Padhani AR, Tanner SF, et al. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol. 1999;72(858):590–597
  81. Kagawa K, Lee WR, Schultheiss TE, et al. Initial clinical assessment of CT-MRI image fusion software in localisation of the prostate for 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;38(2):319–325
  82. Padhani AR, Khoo VS, Suckling J, et al. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys. 1999;44(3):525–533

PII: S0959-8049(05)00051-1

doi: 10.1016/j.ejca.2004.12.028

European Journal of Cancer
Volume 41, Issue 6 , Pages 908-921 , April 2005

Article Tools

* Image Usage & Resolution